Deals
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Under the terms of the deal, Alkermes is paying $100 million in cash upfront. Rodin will be eligible for future payments of up to $850 million based on clinical and regulatory milestones and sales thresholds.
Motif Bio plc of the Company held earlier in New York, all resolutions put to shareholders were duly passed.
Board includes experts from Case Western Reserve University, Duke University, University of Pittsburgh and Washington University in St. Louis
Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.
Establishing a New Gene Therapy Drug Process Development Building and Expanding Product Facilities in Texas, USA
ADL Bionatur Solutions, a company specialized in the research and development of health, cosmetic and beauty products, services and industrial fermentation production, reported financial results for the third quarter and first nine months of 2019.
Leading Patient Experience Platform Advances Company’s Market Position
Strategic investment in the US-based company complements Advanced MedTech’s non-invasive product portfolio and strengthens its leadership in urology and stone management
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.
Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation